Effect of sake yeast supplementation (Saccharomyces cerevisiae) and S-adenosyl methionine (SAM) on pharmacoresistant epilepsy

Investigation of effectiveness of sake yeast supplementation (Saccharomyces cerevisiae) and S-sdenosyl methionine (SAM) in pharmacoresistant epileptic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180119038433N4

Enrollment

120

Registered

2022-01-09

Start date

2022-04-03

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pharmacoresistant epilepsy. Epileptic seizures related to external causes, not intractable, with status epilepticus

Interventions

Intervention 1: Intervention group 1: Sake treatment (12 weeks). Participants who meet the inclusion criteria will be given Sake oral tablets every night for 12 weeks 30 minutes before bedtime. The tr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pharmacoresistant epileptic patients Patients who have not responded to any of the anticonvulsant drugs on the market for at least one year

Exclusion criteria

Exclusion criteria: Cancelation Uncontrolled blood pressure Malignancy History of alcoholism or drug abuse, Pregnancy Lactation Unreliable clinical records Patients who does not take medication Patients who does not attend the clinic orderly

Design outcomes

Primary

Measure	Time frame
Seizure response (daily seizure frequency). Timepoint: Number (frequency) of seizures in patients with drug-resistant epilepsy at the beginning of the study (before the start of the study), at the end of each week after the start of the study and eventually up to two months after the end of the study. Method of measurement: Questionnaire, electroencephalograph (EEG) , physical examination.	—

Secondary

Measure	Time frame
Memory function score. Timepoint: Evaluation of memory function by recording scores in patients with drug-resistant epilepsy at the beginning of the study (before the start of the study), at the end of each week after the start of the study and eventually up to two months after the end of the study. Method of measurement: Questionnaire and physical examination.;Depression score. Timepoint: Evaluation of severity of depression by recording scores in patients with drug-resistant epilepsy at the beginning of the study (before the start of the study), at the end of each week after the start of the study and eventually up to two months after the end of the study. Method of measurement: Questionnaire and physical examination.	—

Measure

Time frame

Memory function score. Timepoint: Evaluation of memory function by recording scores in patients with drug-resistant epilepsy at the beginning of the study (before the start of the study), at the end of each week after the start of the study and eventually up to two months after the end of the study. Method of measurement: Questionnaire and physical examination.;Depression score. Timepoint: Evaluation of severity of depression by recording scores in patients with drug-resistant epilepsy at the beginning of the study (before the start of the study), at the end of each week after the start of the study and eventually up to two months after the end of the study. Method of measurement: Questionnaire and physical examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHooman Bozorgi

Semnan University of Medical Sciences

hoomanbozorgi@semums.ir+98 21 3344 1022

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026